Comment on “Drotrecogin Alfa (activated) (recombinant human protein C, rhAPC) reduces host coagulopathy response in patients with severe sepsis”

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Thrombosis and Haemostasis

• Publication date

  2003-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0037-1613618PMID 14515171
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis

  2003cited by this paper
• Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*

  2003cited by this paper
• Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis

  2003influential reference
• Response of anticoagulant pathways in disseminated intravascular coagulation.

  2001cited by this paper
• Efficacy and safety of recombinant human activated protein C for severe sepsis.

  2001cited by this paper
• Staging of the pathophysiologic responses of the primate microvasculature to Escherichia coli and endotoxin: Examination of the elements of the compensated response and their links to the corresponding uncompensated lethal variants

  2001cited by this paper
• Gene Expression Profile of Antithrombotic Protein C Defines New Mechanisms Modulating Inflammation and Apoptosis*

  2001cited by this paper
• HMG-1 as a mediator of acute lung inflammation.

  2000cited by this paper
• Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli.

  2000cited by this paper
• Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.

  1993cited by this paper

• Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates

  2006cites this paper
• Comparison of mechanisms after post‐hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis

  2004cites this paper
• Mechanism of action of drotrecogin alfa activated (rhAPC)

  2004cites this paper
• Activated protein C in sepsis

  2004cites this paper